The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data
The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading days, and we believe the stock will likely continue to rally in the near term...